New combo therapy shows promise for tough liver cancer cases

This study tested a three-drug approach for people with advanced liver cancer that has spread into the main blood vessel of the liver (portal vein). The treatment combines chemotherapy given directly into the liver artery with two oral drugs (lenvatinib and a PD-1 inhibitor). The goal was to see if this triple therapy works better than just the two oral drugs alone. The study included 66 adults with this specific type of liver cancer and measured how many were still alive without their cancer getting worse after 6 months.